VertexPharma wants to transform the treatment of pain. An upcoming sciatica clinical trial readout will be pivotal.

Vertex Inc. (NASDAQ: VERX) has unveiled a new survey showcasing the critical role of automation and digital transformation in ...

Vertex (VERX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle ...

Vertex (VERX – Research Report), the Technology sector company, was revisited by a Wall Street analyst today. Analyst Chris Quintero from ...

ROI is in the forecast – 49% say they expect to achieve ROI through better forecasting and decision-making, closely followed by a more cost effective and future proofed technology architecture and a ...

On Monday, Vertex Inc (VERX) stock saw a decline, ending the day at $49.29 which represents a decrease of $-2.70 or -5.19% from the prior close of $51.99. The stock opened at $50.35 and touched a low ...

With new approvals on the horizon and the closely watched Casgevy launch picking up steam in sickle cell disease and beta ...

These are the 300 companies whose success goes beyond profits to include employee and customer sentiment, cybersecurity, ...

Good day, and welcome to the Vertex Pharmaceuticals third quarter 2024 earnings call. All participants will be in a ...

Trinasolar, a global leader in smart PV and energy storage solutions, has been awarded the Bankability certificate for its Vertex n-type TOPCon bifacial PV modules by TÜV Rheinland, an independent ...

Vertex achieved its highest level of activity for fiscal 2024 in the current quarter, reporting an adjusted EBITDA (1) of $11.9 million, surpassing the previous company record by $1.0 million. This ...